Novartis targets Alexion's fiefdom after showing PNH patients can safely switch from Soliris

Novartis has presented midphase data showing paroxysmal nocturnal hemoglobinuria (PNH) patients can safely transition from Alexion’s Soliris to its experimental oral candidate LNP023.

The open-label phase 2 evaluated the effect of adding LNP023, Novartis’ small-molecule inhibitor of the alternative complement pathway, to the standard of care in PNH patients. The trial was mainly designed to assess whether daily dosing of LNP023 on top of PNH standard of care, namely Alexion’s blockbuster intravenous infusion Soliris, reduces chronic hemolysis over the first 13 weeks.